Matjaž Brvar

Matjaž Brvar

Auto-generated profile, based on publicly available information

Matjaž Brvar

National Institute of Chemistry, Laboratory for Biocomputing and Bioinformatics, 1001 Ljubljana, Slovenia

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MBMatjaž Brvar
Matjaž Brvar
Andrej PerdihAndrej Perdih
Andrej Perdih
MRMiha Renko
Miha Renko
GAGregor Anderluh
Gregor Anderluh
DTDusan Turk
Dusan Turk
TSTom Solmajer
Tom Solmajer

8 July 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Tihomir TomašičTihomir Tomašič
Tihomir Tomašič
SKSotirios Katsamakas
Sotirios Katsamakas
ŽHŽiga Hodnik
Žiga Hodnik
JIJANEZ ILAŠ
JANEZ ILAŠ
MBMatjaž Brvar
Matjaž Brvar
DKDanijel Kikelj
Danijel Kikelj

15 July 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NZNace Zidar
Nace Zidar
HMHelena Macut
Helena Macut
Tihomir TomašičTihomir Tomašič
Tihomir Tomašič
MBMatjaž Brvar
Matjaž Brvar
SMSofia Montalvão
Sofia Montalvão
DKDanijel Kikelj
Danijel Kikelj

1 December 2017 in Molecular Metabolism
Verified
Journal Article
Open access
MTMette Trauelsen
Mette Trauelsen
EUElisabeth Rexen Ulven
Elisabeth Rexen Ulven
SHSiv A. Hjorth
Siv A. Hjorth
MBMatjaz Brvar
Matjaz Brvar
CMClaudia Monaco
Claudia Monaco
TSThue W. Schwartz
Thue W. Schwartz
Besides functioning as an intracellular metabolite, succinate acts as a stress-induced extracellular signal through activation of GPR91 (SUCNR1) for which we lack suitable pharmacological tools. Here we first determined that the cis conformation of the succinate backbone is preferred and that certain backbone modifications are allowed for GPR91 activation. Through receptor modeling over the X-ray structure of the closely related P2Y1 receptor, we discovered that the binding pocket is partly occupied by a segment of an extracellular loop and that succinate therefore binds in a very different mode than generally believed. Importantly, an empty side-pocket is identified next to the succinate binding site. All this information formed the basis for a substructure-based search query, which, combined with molecular docking, was used in virtual screening of the ZINC database to pick two serial mini-libraries of a total of only 245 compounds from which sub-micromolar, selective GPR91 agonists of unique structures were identified. The best compounds were backbone-modified succinate analogs in which an amide-linked hydrophobic moiety docked into the side-pocket next to succinate as shown by both loss- and gain-of-function mutagenesis. These compounds displayed GPR91-dependent activity in altering cytokine expression in human M2 macrophages similar to succinate, and importantly were devoid of any effect on the major intracellular target, succinate dehydrogenase. These novel, synthetic non-metabolite GPR91 agonists will be valuable both as pharmacological tools to delineate the GPR91-mediated functions of succinate and as leads for the development of GPR91-targeted drugs to potentially treat low grade metabolic inflammation and diabetic complications such as retinopathy and nephropathy.

1 April 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
Žiga JakopinŽiga Jakopin
Žiga Jakopin
JIJANEZ ILAŠ
JANEZ ILAŠ
MBMichaela Barančoková
Michaela Barančoková
MBMatjaž Brvar
Matjaž Brvar
PTPäivi Tammela
Päivi Tammela
DKDanijel Kikelj
Danijel Kikelj
DNA gyrase and topoisomerase IV are type IIa topoisomerases that are essential bacterial enzymes required to oversee the topological state of DNA during transcription and replication processes. Their ATPase domains, GyrB and ParE, respectively, are recognized as viable targets for small molecule inhibitors, however, no synthetic or natural product GyrB/ParE inhibitors have so far reached the clinic for use as novel antibacterial agents, except for novobiocin which was withdrawn from the market. In the present study, a series of substituted oxadiazoles have been designed and synthesized as potential DNA gyrase inhibitors. Structure-based optimization resulted in the identification of compound 35, displaying an IC50 of 1.2 μM for Escherichia coli DNA gyrase, while also exhibiting a balanced low micromolar inhibition of E. coli topoisomerase IV and of the respective Staphylococcus aureus homologues. The most promising inhibitors identified from each series were ultimately evaluated against selected Gram-positive and Gram-negative bacterial strains, of which compound 35 inhibited Enterococcus faecalis with a MIC90 of 75 μM. Our study thus provides further insight into the structural requirements of substituted oxadiazoles for dual inhibition of DNA gyrase and topoisomerase IV.

1 February 2010 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MBMatjaž Brvar
Matjaž Brvar
Andrej PerdihAndrej Perdih
Andrej Perdih
MOMarko Oblak
Marko Oblak
LMLucija Peterlin Mašič
Lucija Peterlin Mašič
TSTom Solmajer
Tom Solmajer